How do I know if my Ovarian Cancer has an actionable mutation

Understanding Actionable Mutations in Ovarian Cancer

This is an excellent question—knowing whether your cancer has an actionable mutation can directly influence your treatment options and outcomes. Let me explain what this means and how to find out.

What Is an "Actionable" Mutation?

An actionable mutation is a genetic change in your cancer cells that doctors can target with specific drugs. Think of it like finding a weakness in the cancer that certain medications are designed to exploit. Without knowing about these mutations, your doctor might miss opportunities for more effective, personalized treatment.

The Most Important Mutations for Ovarian Cancer

According to NCCN Guidelines for Ovarian Cancer, the key mutations your doctors should test for include:

BRCA1/2 Mutations (Most Important)

• These are the most well-established actionable mutations in ovarian cancer
• If you have a BRCA mutation, you may be eligible for PARP inhibitor drugs (like olaparib, rucaparib, or niraparib)
• PARP inhibitors work by preventing cancer cells from repairing DNA damage
• BRCA mutations are found in approximately 15-20% of ovarian cancer patients

Homologous Recombination Deficiency (HRD) Status

• Even without a BRCA mutation, your tumor may have HRD (difficulty repairing DNA)
• HRD status can also predict benefit from PARP inhibitors
• This is increasingly important for patients without BRCA mutations

Other Actionable Mutations (Depending on Your Situation)

According to NCCN Guidelines, additional mutations that may be tested include:

• HER2 status (may guide targeted therapy options)
• Microsatellite Instability (MSI) or Mismatch Repair (MMR) deficiency (may indicate immunotherapy benefit)
• Tumor Mutational Burden (TMB) (emerging biomarker)
• BRAF, NTRK, FRα (FOLR1), RET (in specific situations, especially at recurrence)

When Should You Get Tested?

NCCN Guidelines recommend:

✅ At diagnosis (upfront setting):

• Germline (inherited) BRCA1/2 testing
• Somatic (tumor) BRCA1/2 testing
• HRD status testing (if no BRCA mutation found)

✅ At recurrence or progression:

• More comprehensive tumor molecular analysis
• Testing for additional mutations listed above
• This is especially important if your cancer returns after initial treatment

How the Testing Works

Two types of testing:

1. Germline Testing (blood test)

   • Checks if you inherited a BRCA mutation
   • Important for your family members and future cancer risk
   • Results are permanent and don't change

2. Somatic Testing (tumor tissue analysis)

   • Analyzes the cancer cells themselves
   • Performed on your most recent tumor tissue
   • Can be done on tissue from surgery or biopsy
   • May also be done on circulating tumor DNA (liquid biopsy) if tissue isn't available

According to NCCN Guidelines, testing should be performed in a CLIA-approved laboratory (Clinical Laboratory Improvement Amendments—this ensures quality standards).

What to Ask Your Oncology Team

Since YOUR specific situation requires your doctor's evaluation, here are critical questions to ask:

1. "Has my tumor been tested for BRCA mutations and HRD status?" If not, why not?

2. "What mutations were found in my tumor, and what do they mean for my treatment options?"

3. "Am I eligible for PARP inhibitor maintenance therapy based on my mutation status?"

4. "If I don't have a BRCA mutation, what is my HRD status, and does that change my treatment?"

5. "Should I have germline genetic testing, and if so, should I see a genetic counselor?"

6. "If my cancer recurs, will you do additional molecular testing to look for new mutations?"

Why This Matters for Your Treatment

According to NCCN Guidelines, if you have:

• BRCA mutation + complete or partial response to first-line chemotherapy → PARP inhibitors (olaparib, rucaparib, or niraparib) are recommended as maintenance therapy
• HRD-positive status (without BRCA) → PARP inhibitors may still provide benefit, though typically less dramatic than with BRCA mutations
• Other mutations → May open doors to clinical trials or emerging targeted therapies

Getting Your Results

Make sure you:

• Request a copy of your molecular testing report
• Ask your doctor to explain each result in plain language
• Understand which mutations are actionable vs. which are being monitored
• Know whether additional testing is recommended

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Sources cited:

• NCCN Guidelines Version 3.2025: Ovarian Cancer (Molecular Testing recommendations)
• NCCN Guidelines: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer